Hypertension is the most common cardiovascular diseases, moreover hypertension is a major risk factor for coronary artery disease and its complications. Hypertension prevalence increases with advancing age. Atenolol is a competitive beta (1) -selective adrenergic antagonists and has been widely used in hypertension therapy. Administration of conventional tablets of atenolol has been reported to exhibit poor patient compliance in geriatric patients. The aim of this study was to formulate and evaluate orally disintegrating tablets of atenolol to overcome poor patient compliance in geriatric patients. In this study, crospovidone were used as superdisintegrant in two different concentrations (10% and 20%). Formula 1 using 0% of crospovidone, formula 2 using 10% of crospovidone, and formula 3 using 20% of crospovidone. It was found that there was significant difference of wetting time, water absorption ratio, in vitro dispersion time, and dissolution parameters (area under curve value (AUC) and dissolution efficiency (ED)) among these formulas. Formula 2 which used 10% crospovidone showed the best physichochemical characteristics and met all requirements of orally disintegrating tablets. Dissolution efficiency of formula 2 (10% crospovidone) increased approximately 2 times compared to formula 1 (0% crospovidone), moreover dissolution efficiency of formula 2 increased 1.25 times compared to formula 3 (20% crospovidone)
